Intravoxel Incoherent Motion MRI As a Biomarker of Sorafenib Treatment for Advanced Hepatocellular Carcinoma: a Pilot Study

Overview

Journal Cancer Imaging

Publisher Springer Nature

Specialties Oncology
Radiology

Date 2016 Jan 30

PMID 26822946

Citations 26

Authors

Natsuhiko Shirota

Kazuhiro Saito

Katsutoshi Sugimoto

Kenichi Takara

Fuminori Moriyasu

Koichi Tokuuye

Affiliations

Soon will be listed here.

Abstract

Background: To evaluate the association between the therapeutic outcomes of sorafenib for advanced hepatocellular carcinoma (HCC) and the parameters of intravoxel incoherent motion (IVIM).

Methods: Nine patients were evaluated prospectively. All patients were Child-Pugh score A. The mean dimension of the lesion was 32 mm (range: 15-74 mm). MR images were obtained using a 1.5-Tesla superconductive MRI system. Diffusion-weighted imaging was performed under breath-holding using b-values of 0, 50, 100, 150, 200, 400, and 800 s/mm(2). The following IVIM parameters were calculated: apparent diffusion coefficient, true diffusion coefficient (DC), pseudo-diffusion coefficient, and perfusion fraction. MRI was performed before treatment and at 1, 2, and 4 weeks after beginning treatment. Tumor response at 4 weeks was assessed by CT or MRI using modified RECIST. IVIM parameters of the treatment responders and non-responders were compared.

Results: The DC of responders at baseline was significantly higher than that of the non-responders. The sensitivity and specificity, when a DC of 0.8 (10(-3) mm(2)/s) or higher was considered to be a responder, were 100 % and 67 %, respectively. No significant differences were found in the other parameters between the responders and the non-responders. All IVIM parameters of the responders and non-responders did not change significantly after treatment.

Conclusion: The DC before treatment may be a useful parameter for predicting the therapeutic outcome of sorafenib for advanced HCC.

Citing Articles

CT and MRI of abdominal cancers: current trends and perspectives in the era of radiomics and artificial intelligence.

Barat M, Pellat A, Hoeffel C, Dohan A, Coriat R, Fishman E Jpn J Radiol. 2023; 42(3):246-260.

PMID: 37926780 DOI: 10.1007/s11604-023-01504-0.

Intravoxel Incoherent Motion Factors Affecting Collapse and Nonunion of Osteoporotic Vertebral Fracture.

Ogon I, Takebayashi T, Takashima H, Abe Y, Oguma H, Imamura R Global Spine J. 2023; 14(7):2074-2080.

PMID: 37001146 PMC: 11418743. DOI: 10.1177/21925682231167788.

Application of Intravoxel Incoherent Motion in the Evaluation of Hepatocellular Carcinoma after Transarterial Chemoembolization.

Yue X, Lu Y, Jiang Q, Dong X, Kan X, Wu J Curr Oncol. 2022; 29(12):9855-9866.

PMID: 36547188 PMC: 9776688. DOI: 10.3390/curroncol29120774.

Intravoxel incoherent motion to differentiate spinal metastasis: A pilot study.

Zhang E, Li Y, Xing X, Qin S, Yuan H, Lang N Front Oncol. 2022; 12:1012440.

PMID: 36276105 PMC: 9582254. DOI: 10.3389/fonc.2022.1012440.

Application of intravoxel incoherent motion diffusion-weighted imaging in hepatocellular carcinoma.

Zhou Y, Zheng J, Yang C, Peng J, Liu N, Yang L World J Gastroenterol. 2022; 28(27):3334-3345.

PMID: 36158259 PMC: 9346463. DOI: 10.3748/wjg.v28.i27.3334.

References

Jain R . Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307(5706):58-62. DOI: 10.1126/science.1104819. View

Ichikawa T, Arbab A, Araki T, Touyama K, Haradome H, Hachiya J . Perfusion MR imaging with a superparamagnetic iron oxide using T2-weighted and susceptibility-sensitive echoplanar sequences: evaluation of tumor vascularity in hepatocellular carcinoma. AJR Am J Roentgenol. 1999; 173(1):207-13. DOI: 10.2214/ajr.173.1.10397128. View

Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith R . Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006; 5(10):835-44. DOI: 10.1038/nrd2130. View

Koh D, Collins D . Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007; 188(6):1622-35. DOI: 10.2214/AJR.06.1403. View

Yanaga Y, Awai K, Nakaura T, Namimoto T, Oda S, Funama Y . Optimal contrast dose for depiction of hypervascular hepatocellular carcinoma at dynamic CT using 64-MDCT. AJR Am J Roentgenol. 2008; 190(4):1003-9. DOI: 10.2214/AJR.07.3129. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Luciani A, Vignaud A, Cavet M, Tran Van Nhieu J, Mallat A, Ruel L . Liver cirrhosis: intravoxel incoherent motion MR imaging--pilot study. Radiology. 2008; 249(3):891-9. DOI: 10.1148/radiol.2493080080. View

Schraml C, Schwenzer N, Martirosian P, Bitzer M, Lauer U, Claussen C . Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol. 2009; 193(4):W301-7. DOI: 10.2214/AJR.08.2289. View

Lencioni R, Llovet J . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):52-60. DOI: 10.1055/s-0030-1247132. View

10.

Spira D, Fenchel M, Lauer U, Claussen C, Gregor M, Bitzer M . Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad Radiol. 2010; 18(1):89-96. DOI: 10.1016/j.acra.2010.08.008. View

11.

Lewin M, Fartoux L, Vignaud A, Arrive L, Menu Y, Rosmorduc O . The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. Eur Radiol. 2010; 21(2):281-90. DOI: 10.1007/s00330-010-1914-4. View

12.

Goh V, Sarker D, Osmany S, Cook G . Functional imaging techniques in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2012; 39(6):1070-9. DOI: 10.1007/s00259-012-2096-x. View

13.

Kim S, Lee S, Park B, Kim N, Kim J, Park S . Reproducibility of measurement of apparent diffusion coefficients of malignant hepatic tumors: effect of DWI techniques and calculation methods. J Magn Reson Imaging. 2012; 36(5):1131-8. DOI: 10.1002/jmri.23744. View

14.

Andreou A, Koh D, Collins D, Blackledge M, Wallace T, Leach M . Measurement reproducibility of perfusion fraction and pseudodiffusion coefficient derived by intravoxel incoherent motion diffusion-weighted MR imaging in normal liver and metastases. Eur Radiol. 2012; 23(2):428-34. DOI: 10.1007/s00330-012-2604-1. View

15.

Woo S, Lee J, Yoon J, Joo I, Han J, Choi B . Intravoxel incoherent motion diffusion-weighted MR imaging of hepatocellular carcinoma: correlation with enhancement degree and histologic grade. Radiology. 2014; 270(3):758-67. DOI: 10.1148/radiol.13130444. View

16.

Dzik-Jurasz A, Domenig C, George M, Wolber J, Padhani A, Brown G . Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet. 2002; 360(9329):307-8. DOI: 10.1016/S0140-6736(02)09520-X. View

17.

Yamashita Y, Komohara Y, Takahashi M, Uchida M, Hayabuchi N, Shimizu T . Abdominal helical CT: evaluation of optimal doses of intravenous contrast material--a prospective randomized study. Radiology. 2000; 216(3):718-23. DOI: 10.1148/radiology.216.3.r00se26718. View

18.

Takeda H, Nishikawa H, Osaki Y, Tsuchiya K, Joko K, Ogawa C . Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. Liver Int. 2014; 35(5):1581-9. DOI: 10.1111/liv.12591. View

19.

Mardor Y, Roth Y, Ochershvilli A, Spiegelmann R, Tichler T, Daniels D . Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI. Neoplasia. 2004; 6(2):136-42. PMC: 1502089. DOI: 10.1593/neo.03349. View

20.

Le Bihan D, Breton E, lAllemand D, Aubin M, VIGNAUD J, LAVAL-JEANTET M . Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology. 1988; 168(2):497-505. DOI: 10.1148/radiology.168.2.3393671. View